Tewksbury, MA, United States of America

Xiangyang Tan


 

Average Co-Inventor Count = 4.5

ph-index = 3

Forward Citations = 15(Granted Patents)


Company Filing History:


Years Active: 2015-2024

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: **Innovative Contributions of Xiangyang Tan in Biotechnology**

Introduction

Xiangyang Tan is a distinguished inventor based in Tewksbury, MA, USA, recognized for his impactful contributions to biotechnology through his work in antibody development. With a portfolio of six patents, Tan has consistently pushed the boundaries of innovation to tackle significant challenges in the medical field.

Latest Patents

Tan's latest innovations include the development of Anti-IL-17A antibodies, specifically designed to bind to IL-17A with high affinity. This patent not only covers the antibody itself but also encompasses methods for its preparation and use. Another notable patent is focused on methods of blocking cancer stem cell growth. This patent discloses antibodies against GPR49 and outlines various applications, including the development of monoclonal, humanized, or fully human antibodies. Additionally, it details hybridomas, nucleic acids, and methods for leveraging these antibodies to combat cancer stem cell proliferation.

Career Highlights

Xiangyang Tan has made significant strides in the field while working at Bionomics Inc., a company dedicated to advancing biotechnology solutions. His dedication and innovative spirit have positioned him as a key figure in the pursuit of groundbreaking biopharmaceutical treatments.

Collaborations

Throughout his career, Tan has collaborated with notable professionals, including Christopher L Reyes and Peter Chu. These collaborations have fostered an environment of innovation and have contributed to the development of remarkable biotechnological advancements.

Conclusion

Xiangyang Tan stands as a testament to the power of innovation in the biopharmaceutical industry. His patents and collaborative efforts reflect a commitment to advancing medical research and improving patient outcomes through cutting-edge technology. As he continues his work at Bionomics Inc., the field eagerly anticipates the future innovations he will bring forth.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…